A new trading day began on Tuesday, with Boston Scientific Corp (NYSE: BSX) stock price up 1.36% from the previous day of trading, before settling in for the closing price of $94.95. BSX’s price has ranged from $80.64 to $109.50 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -17.84%. Meanwhile, its annual earnings per share averaged 18.83%. With a float of $1.48 billion, this company’s outstanding shares have now reached $1.48 billion.
Boston Scientific Corp (BSX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Boston Scientific Corp is 0.41%, while institutional ownership is 92.39%. The most recent insider transaction that took place on Oct 01 ’25, was worth 4,923,327. In this transaction EVP & Group Pres, Cardiology of this company sold 50,000 shares at a rate of $98.47, taking the stock ownership to the 178,342 shares. Before that another transaction happened on Oct 01 ’25, when Company’s Officer proposed sale 50,000 for $98.47, making the entire transaction worth $4,923,325.
Boston Scientific Corp (BSX) Performance Highlights and Predictions
In its latest quarterly report, released on 9/30/2024, the company reported earnings of 0.63 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.76 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.42% during the next five years compared to -17.84% drop over the previous five years of trading.
Boston Scientific Corp (NYSE: BSX) Trading Performance Indicators
Here are Boston Scientific Corp’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.71. Likewise, its price to free cash flow for the trailing twelve months is 40.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.68, a number that is poised to hit 0.71 in the next quarter and is forecasted to reach 3.41 in one year’s time.
